Last reviewed · How we verify
HAT1
At a glance
| Generic name | HAT1 |
|---|---|
| Also known as | HAT01 |
| Sponsor | Haus Bioceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis (PHASE4)
- Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis (PHASE2)
- A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests (PHASE4)
- Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis (PHASE1,PHASE2)
- Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |